Brigitte Nault

TL;DR: To investigate the efficacy and safety of tegaserod, a novel 5‐HT4 receptor partial agonist, in a randomized, double‐blind, placebo‐controlled, 12‐week treatment, multicentre study.

TL;DR: Tegaserod was efficacious in relieving symptoms of chronic constipation and was well tolerated and significant improvements were also seen in stool form and in global assessment of bowel habits and constipation.

TL;DR: Tegaserod treatment produced significant improvements in chronic constipation symptoms and was also safe and well tolerated; headache and nasopharyngitis, the most frequent adverse events, were more common in the placebo group than in either tegaserod group.

TL;DR: Tegaserod is a 5‐hydroxytryptamine‐4 receptor partial agonist that causes gastrointestinal effects resulting in increased gastrointestinal motility and attenuation of visceral sensation.

TL;DR: Tegaserod is effective in relieving the multiple symptoms of constipation: results from a 12-week multinational study in patients with chronic constipation.